Data, Registries and Advocacy for Hurler Syndrome

Data, registries and advocacy for Hurler syndrome (MPS I-H)

Strong data can change lives. In Hurler syndrome, carefully collected clinical information, long-term registries and coordinated advocacy help improve diagnosis, access to treatment and long-term outcomes for children, adults and families.

This page explains how registries and data are used in MPS I-H, why participation matters, and how shared evidence supports real-world change.

For families, patient advocates, clinicians and researchers interested in data, policy and long-term follow-up in MPS I-H.
Data & people connected

Why data is so important in a rare disease

Hurler syndrome is extremely rare. No single hospital or country can answer all clinical questions alone. By combining information across centres and over time, meaningful patterns begin to emerge.

  • Shared data shows trends beyond individual patients or clinics.
  • Registries allow long-term follow-up from childhood into adulthood.
  • High-quality evidence supports access to new therapies and fair funding.
  • Clear data strengthens the collective voice of the MPS I-H community.

Long-term outcomes | Unmet need

What is a Hurler syndrome registry?

A registry is a secure system that gathers structured information about people living with Hurler syndrome. The goal is to understand the condition better, improve care and guide future research.

  • Basic background such as birth year, sex and country
  • Diagnostic results including enzyme and genetic testing
  • Treatment history such as HSCT or enzyme replacement therapy
  • Ongoing follow-up of organs, development and quality of life
  • Hospitalisations, surgeries and clinical complications

Personal details are usually coded before analysis. Each registry follows defined consent and data-protection standards.

Follow up & registries | Biomarkers & outcomes

How registry data are used

  • Understanding survival and long-term outcomes after HSCT or ERT
  • Tracking frequency of surgeries, hospital stays and complications
  • Identifying common heart, lung, bone and neurological issues
  • Measuring impact on education, work and daily independence
  • Comparing care approaches between centres and countries

Registry findings inform guidelines, funding decisions and the design of future clinical trials.

Multisystem management | Clinical trials

How families help shape the future

Registries rely on families who are willing to share information and remain connected with specialist teams over time.

  • Participation is voluntary and withdrawal is always possible.
  • Individual data are confidential, but combined results benefit all.
  • Positive outcomes show what is achievable for newly diagnosed families.
  • Challenges highlight areas where care urgently needs improvement.

Living with Hurler syndrome | Patient stories

Turning numbers into change

Advocacy transforms data and lived experience into better policies, services and access to treatment.

  • Demonstrating that MPS I-H remains lifelong despite treatment
  • Providing real-world evidence of care and support needs
  • Highlighting inequalities between regions and health systems
  • Supporting decisions on funding therapies and newborn screening

Privacy, consent and trust

  • Clear information on what data are collected and why
  • Secure storage and restricted access
  • Pseudonymisation wherever possible
  • The right to withdraw from future analyses
Scroll to Top